Paper Details

  1. Home
  2. Paper Details

Antitumor and normal cell protective effect of PKC412 in the athymic mouse model of ovarian cancer.

Author: ChungWon Heui, HanKu Taek, HanKyungja, KimMyungshin, KimYonggoo, LimJihyang, ParkIn-Yang

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study examines the antitumor effects of PKC412, a protein kinase C inhibitor, alone and in combination with paclitaxel in a mouse model of ovarian cancer. The combination demonstrated synergistic effects in reducing tumor burden and mitigating paclitaxel-induced side effects, suggesting potential clinical application.
Paper Details　
Original Abstract of the Article :
N-benzoyl-staurosporine (PKC412) is a selective inhibitor of protein kinase C, and it inhibits the growth of human cancer cells. In this study, we examined the antitumor effect of PKC412, given singly and in combination with paclitaxel, on tumor regression and chemotherapeutic side effects by assess...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/17127735

データ提供：米国国立医学図書館（NLM）

PKC412: A Promising Ally in the Fight Against Ovarian Cancer

Ovarian cancer is a formidable adversary, and finding effective treatments remains a top priority in oncology. This study investigates the potential of a drug called PKC412, known to inhibit protein kinase C, in combating ovarian cancer. Researchers tested PKC412 alone and in combination with paclitaxel, a common chemotherapy drug, in a mouse model of ovarian cancer. The researchers meticulously measured tumor growth and various immune system indicators to assess the drugs' effectiveness. The results showed that PKC412 alone had a limited impact on tumor growth, but when combined with paclitaxel, it significantly reduced tumor burden and lessened the side effects of chemotherapy. These findings suggest that PKC412 could be a valuable adjunct to paclitaxel in treating ovarian cancer.

A Multi-faceted Approach to Cancer Treatment

The study highlights the importance of considering combination therapies to improve cancer treatment outcomes. PKC412's ability to enhance the effectiveness of chemotherapy while mitigating its side effects makes it a promising candidate for future clinical trials.

Hope on the Horizon for Ovarian Cancer Patients

This research offers a glimmer of hope for patients battling ovarian cancer. While more research is needed to fully understand the potential of PKC412, it represents a promising avenue for developing more effective and less toxic treatment strategies. Just as a camel adapts to the harsh desert environment, researchers are constantly searching for ways to enhance our understanding of cancer and develop new therapies that can improve patient outcomes.

Dr. Camel's Conclusion

The fight against cancer is like navigating a vast and unforgiving desert. This research offers a promising oasis, suggesting that PKC412 could be a valuable ally in the fight against ovarian cancer. We continue to search for innovative strategies that can help patients overcome this challenging disease, and this study provides a roadmap for future exploration.

Date :
  1. Date Completed 2007-01-09
  2. Date Revised 2016-11-24
Further Info :

Pubmed ID

17127735

DOI: Digital Object Identifier

36/4/455

Related Literature

Article Analysis
・Side Effects of midostaurin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.